Summary of Patient Clinical Data and Proliferative Responses
| Proliferative responses to: . | . | PHA only . | . | PHA and tetanus toxoid only . | . | PHA, tetanus toxoid, and HIV antigens . | . | Total . |
|---|---|---|---|---|---|---|---|---|
| No. of patients | 19 (44%) | 12 (28%) | 12 (28%) | 43 | ||||
| Mean CD4 counts (cells/μl) | 351 ± 169 | 350 ± 153 | 497 ± 148 | 398 ± 167 | ||||
| Length of time of infection (yr) | <1–10 | <1–8 | <1–4 | <1–10 | ||||
| Mean proliferation (SI) to: | ||||||||
| PHA | 49 ± 53 | 78 ± 118 | 138 ± 170 | 82 ± 118 | ||||
| Tetanus toxoid | <1 | 45 ± 117 | 31 ± 32 | 21 ± 65 | ||||
| HIV antigens | <1 | <1 | 15 ± 18 | 5 ± 11 |
| Proliferative responses to: . | . | PHA only . | . | PHA and tetanus toxoid only . | . | PHA, tetanus toxoid, and HIV antigens . | . | Total . |
|---|---|---|---|---|---|---|---|---|
| No. of patients | 19 (44%) | 12 (28%) | 12 (28%) | 43 | ||||
| Mean CD4 counts (cells/μl) | 351 ± 169 | 350 ± 153 | 497 ± 148 | 398 ± 167 | ||||
| Length of time of infection (yr) | <1–10 | <1–8 | <1–4 | <1–10 | ||||
| Mean proliferation (SI) to: | ||||||||
| PHA | 49 ± 53 | 78 ± 118 | 138 ± 170 | 82 ± 118 | ||||
| Tetanus toxoid | <1 | 45 ± 117 | 31 ± 32 | 21 ± 65 | ||||
| HIV antigens | <1 | <1 | 15 ± 18 | 5 ± 11 |
Results are expressed as SI = mean cpm of PBMCs plus antigen/mean cpm of PBMCs alone. HIV antigens, pools of overlapping peptides covering all of Gag p24 or Gag p17.